The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.

Pyxis Oncology, a US-based cancer treatment developer utilising research from University of Chicago, has received $152m in a series B round featuring pharmaceutical firms Ipsen and Pfizer as well as pharmaceutical and chemical group Bayer. Arix Bioscience and RTW Investments co-led the round, which was also backed by Perceptive Advisors, RA Capital Management, BVF Partners,…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.